13) Chemical Therapeutics
Abstract
Focuses on therapeutic strategies to effectively minimize neurologic injuries resulting from exposure to CWAs. This effort involves the development of neuroprotectants, anticonvulsants, and improved neurotransmitter restorers. This work is designed to develop potential candidates that will ultimately be submitted for Food and Drug Administration (FDA) licensure or new indications for previously licensed products for use in the treatment of chemical warfare casualties.
Document Details
- Document Type
- Accomplishment
- Publication Date
- Oct 01, 2016
- Source ID
- f7e0251d5f4fa2a80227277480ee9ffc